



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Gaia Giannone

✉ g.giannone@imperial.ac.uk

RECEIVED 18 December 2023

ACCEPTED 19 December 2023

PUBLISHED 22 January 2024

## CITATION

Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetti M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutati V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S and Valabrega G (2024)

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.

*Front. Oncol.* 13:1357793.

doi: 10.3389/fonc.2023.1357793

## COPYRIGHT

© 2024 Arezzo, Giannone, Castaldo, Scotto, Tuninetti, Turinetti, Bartoletti, Mammoliti, Artioli, Mangili, Salutati, Lorusso, Cormio, Loizzi, Zamagni, Savarese, Di Maio, Ronzino, Pisano, Pignata and Valabrega. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors

Francesca Arezzo<sup>1,2</sup>, Gaia Giannone<sup>3\*</sup>, Daniele Castaldo<sup>4</sup>, Giulia Scotto<sup>5</sup>, Valentina Tuninetti<sup>6</sup>, Margherita Turinetti<sup>5</sup>, Michele Bartoletti<sup>7</sup>, Serafina Mammoliti<sup>8</sup>, Grazia Artioli<sup>9</sup>, Giorgia Mangili<sup>10</sup>, Vanda Salutati<sup>11</sup>, Domenica Lorusso<sup>12</sup>, Gennaro Cormio<sup>1,13</sup>, Vera Loizzi<sup>1,13</sup>, Claudio Zamagni<sup>14</sup>, Antonella Savarese<sup>15</sup>, Massimo Di Maio<sup>6</sup>, Graziana Ronzino<sup>16</sup>, Carmela Pisano<sup>17</sup>, Sandro Pignata<sup>17</sup> and Giorgio Valabrega<sup>6</sup>

<sup>1</sup>Gynecologic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy, <sup>2</sup>Department of Precision and Regenerative Medicine – Ionian Area, University of Bari "Aldo Moro", Bari, Italy,

<sup>3</sup>Department of Surgery and Cancer, Imperial College London, London, United Kingdom, <sup>4</sup>Segreteria Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) Group, Naples, Italy,

<sup>5</sup>Department of Oncology, University of Turin, Turin, Italy, <sup>6</sup>Department of Oncology, Maurizio Hospital, University of Turin, Turin, Italy, <sup>7</sup>Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy, <sup>8</sup>Ospedale Policlinico San Martino - Department of Medical Oncology, IRCCS, Genoa, Italy, <sup>9</sup>Oncologia Medica, Unità locale socio sanitaria n2 (ULSS2) Marca Trevigiana, Treviso, Italy, <sup>10</sup>Obstet-Gynecol Department, San Raffaele Scientific Institute, IRCCS, Milan, Italy,

<sup>11</sup>Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy, <sup>12</sup>Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy, <sup>13</sup>Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy, <sup>14</sup>Azienda Ospedaliero-universitaria di Bologna, IRCCS, Bologna, Italy, <sup>15</sup>Department of Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy, <sup>16</sup>Department of Oncology, Ospedale "Vito Fazzi", Lecce, Italy, <sup>17</sup>Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli, Naples, Italy

## KEYWORDS

endometrial cancer, molecular classification, immune checkpoint inhibitors, dostarlimab, pembrolizumab plus lenvatinib

## A Corrigendum on

### Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors

by Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetti M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutati V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S and Valabrega G (2023) *Front. Oncol.* 13:1247291. doi: 10.3389/fonc.2023.1247291

In the published article, there was an error in affiliation 15. Instead of “Department of Oncology, Regina Elena National Cancer Institute, Rome, Italy”, it should be “Department of Oncology, IRCCS Regina Elena National Cancer Institute-Rome, Italy.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.